Format:
Online-Ressource (X, 369 p. 59 illus., 39 illus. in color, digital)
ISBN:
9781461453802
Series Statement:
SpringerLink
Content:
Development of new-generation vaccines is now more challenging than ever, as identifying, purifying and evaluating vaccine antigens is a complex undertaking. Most importantly, once the relevant antigens have been identified, key focus then shifts to the development of suitable delivery systems and formulations to achieve maximum in vivo potency with minimum potential side effects. These novel formulations--many of which will be nanoparticulates--can deliver the antigens to the desired site, to the relevant antigen presenting cells, and prevent systemic exposure of the immune potentiators. The proposed book will outline all the critical steps that need to be considered for successful development of various types of nanoparticulate delivery systems for vaccine antigens. These contributions from leading experts in the area of vaccine formulation and delivery systems will tie in what is the most current status, including clinical evaluations with these novel vaccine technologies
Content:
Development of new-generation vaccines is now more challenging than ever, as identifying, purifying and evaluating vaccine antigens is a complex undertaking. Most importantly, once the relevant antigens have been identified, key focus then shifts to the development of suitable delivery systems and formulations to achieve maximum in vivo potency with minimum potential side effects. These novel formulations-many of which will be nanoparticulates-can deliver the antigens to the desired site, to the relevant antigen presenting cells, and prevent systemic exposure of the immune potentiators. The proposed book will outline all the critical steps that need to be considered for successful development of various types of nanoparticulate delivery systems for vaccine antigens. These contributions from leading experts in the area of vaccine formulation and delivery systems will tie in what is the most current status, including clinical evaluations with these novel vaccine technologies.
Note:
Includes index
,
Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines; Preface; Contents; Contributors; Section I: Novel Immune Potentiators and Delivery Systems for Enhancing Vaccine Potency; Chapter 1: TLR7/8 Agonists as Vaccine Adjuvants; 1.1 Introduction; 1.2 The Need for New Vaccine Adjuvants; 1.3 Toll-Like Receptors and Toll-Like Receptor Agonists; 1.4 TLR Agonists as Vaccine Adjuvants; 1.5 Small Molecule TLR7, TLR8, and TLR7/8 Agonists as Vaccine Adjuvants; 1.6 Resiquimod as a Vaccine Adjuvant; 1.7 Novel Imidazoquinolines as Vaccine Adjuvants; 1.8 Conclusion; References
,
Chapter 2: Preclinical and Clinical Development of Synthetic i NKT-Cell Glycolipid Agonists as Vaccine Adjuvants2.1 Introduction; a -GalCer Structure; 2.2 Preclinical and Clinical Experience with Soluble a -GalCer as Vaccine Adjuvant; 2.2.1 Preclinical Studies with Soluble a -GalCer; 2.2.1.1 Antitumour Immunity; a -GalCer as Adjuvant with DNA Vaccines; a -GalCer as Adjuvant with Irradiated Tumour Cells as Antigens; a -GalCer as Adjuvant Combined to Nontoxic B Subunit of Shiga Toxin-Based Vaccines; 2.2.1.2 Anti-infectious Immunity; α -GalCer as Adjuvant for HIV Vaccines
,
α -GalCer as Adjuvant for Malaria Vaccinesα -GalCer as Adjuvant for Bacillus anthracis Vaccine; α -GalCer as Adjuvant for Genital Herpes Vaccine; α -GalCer as Adjuvant for In fl uenza Vaccines; α -GalCer as a Mucosal Adjuvant; α -GalCer Adjuvant in Subcutaneous Immunization; 2.2.2 Clinical Experience with Free a -GalCer as a Drug; 2.2.2.1 Patients with Refractory Solid Tumours; 2.2.2.2 Patients with Chronic Hepatitis B Infection; 2.2.2.3 Patients with Chronic Hepatitis C Infection; 2.3 Preclinical and Clinical Experience with Glycolipid-Loaded or Transduced Cells
,
2.3.1 Preclinical Experience with a -GalCer-Loaded and a -GalCer-Transduced Cells2.3.1.1 α -GalCer-Loaded Tumour Cells; 2.3.1.2 α -GalCer-Loaded Myeloid-Derived Suppressor Cells; 2.3.1.3 α -GalCer-Loaded B Cells; 2.3.1.4 α -GalCer-Loaded Antigen-Transduced B Cells; 2.3.1.5 Allogeneic Fibroblasts Transfected with Antigen-Encoding mRNA, Loaded with a -GalCer; 2.3.1.6 α -GalCer Transduced in Live Vectors; 2.3.1.7 Glycolipid-Loaded DC; α -GalCer-Loaded Cells Derived from Mouse Embryonic Stem Cells; α -GalCer-Loaded DC; 2.3.2 Clinical Experience with Glycolipid-Loaded DC
,
2.3.2.1 α -GalCer-Pulsed Immature Monocyte-Derived DC2.3.2.2 α -GalCer Loaded Monocyte-Derived Mature DC; 2.3.2.3 α -GalCer-Pulsed IL-2/GM-CSF-Cultured PBMCs Containing DCs; 2.3.2.4 α -GalCer-Pulsed Antigen-Presenting Cells; 2.4 Combination Therapies with Glycolipids and Other Adjuvants; 2.4.1 α -GalCer and TLR Ligands; 2.4.2 α -GalCer and Quil A; 2.4.3 Combination of DC Immunization with a -GalCer; 2.5 α - GalCer Bound to Soluble CD1d; 2.6 Oral and Intranasal Administration of α -GalCer; 2.7 Analogues of a -GalCer with C Glycosidic Linkage
,
2.7.1 α -C-GalCer as Adjuvant for Malaria and Tumour Vaccines
,
Critical parameters that govern the optimization of vaccine formulations -- Development of Biophysical assays to better understand vaccine formulation stability -- Rational design of vaccine formulations -- Monitoring stability and efficacy of multi-valent vaccine formulations.- Overcoming challenges of multi component alum formulations.- Delivery of various TLR adjuvants using alum platform -- History of use of emulsions for vaccine delivery -- MF59 o/w emulsion : History and safety over the last 2 decades -- Optimizing novel nanoemulsions for delivery of next generation antigens and adjuvants -- Modulating vaccine responses with innate immunity : Use of PLGA nanoparticles for delivering multiple TLR agonists -- Shape matters : Role of nanoparticle shape in induction of immune responses to a vaccine. .
Additional Edition:
ISBN 9781461453796
Additional Edition:
Erscheint auch als Druck-Ausgabe ISBN 978-1-461-45379-6
Language:
English
DOI:
10.1007/978-1-4614-5380-2
URL:
Volltext
(lizenzpflichtig)
